Basic Information


GTO ID GTC3414
Trial ID NCT05827068
Disease Seasonal Influenza
TherapymRNA vaccine
Treatment mRNA-1010;mRNA-1011.1;mRNA-1011.2;mRNA-1012.1
PhasePhase1|Phase2
Recruitment statusCompleted
TitleA Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age
Year2023
CountryUnited States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-1011-P101
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: mRNA-1011.1
Administration route intramuscular injection
Dosage mRNA-1011.1, on Day 1
Age Adult, Older_Adult
Cohort2: mRNA-1011.2
Administration route intramuscular injection
Dosage mRNA-1011.2, on Day 1
Age Adult, Older_Adult
Cohort3: mRNA-1012.1
Administration route intramuscular injection
Dosage mRNA-1012.1, on Day 1
Age Adult, Older_Adult
Cohort4: mRNA-1010
Administration route intramuscular injection
Dosage mRNA-1010, on Day 1
Age Adult, Older_Adult
Cohort5: mRNA-1010.2
Administration route intramuscular injection
Dosage mRNA-1010.2, on Day 1
Age Adult, Older_Adult
Cohort6: mRNA-1010.3
Administration route intramuscular injection
Dosage mRNA-1010.3, on Day 1
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph